Trius Therapeutics

The lead compound from Trius, tedizolid phosphate (formerly torezolid phosphate, TR-701), successfully completed its first Phase 3 clinical trial (ESTABLISH 1) in acute skin and skin structure infections (ABSSSI). It is a once daily, IV and oral, oxazolidinone being developed for the treatment of serious gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The Phase 3 trials are being conducted under a Special Protocol Agreement with the US Food and Drug Administration and are using the draft FDA guidance of cessations of lesion spread at 48–72 hours as the primary endpoint. In the ESTABLISH 1 Study, 200 mg of Tedizolid given for a short course of therapy (six days) was shown to be safe, well tolerated and was as effective as the traditional length of therapy with linezolid (600 mg for ten days). Additionally, Tedizolid was shown to have fewer treatment-related side effects than linezolid and significantly fewer GI side effects.

Trius was planning the second Phase 2 trial and expects to report results around the end of Q1 2013 and planned to submit an NDA to the FDA for the drug in the second half of 2013.

Tedizolid was approved by the US Food and Drug Administration on June 20, 2014.

The firm was acquired by Cubist Pharmaceuticals at the end of July 2013 in a deal worth $1.6 billion. This fee also included the purchase of Optimer Pharmaceuticals.